CN104955831A - 新型类黄酮化合物及其用途 - Google Patents

新型类黄酮化合物及其用途 Download PDF

Info

Publication number
CN104955831A
CN104955831A CN201380058798.9A CN201380058798A CN104955831A CN 104955831 A CN104955831 A CN 104955831A CN 201380058798 A CN201380058798 A CN 201380058798A CN 104955831 A CN104955831 A CN 104955831A
Authority
CN
China
Prior art keywords
compound
disease
group
sugar
kinds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380058798.9A
Other languages
English (en)
Chinese (zh)
Inventor
格兰特·安德鲁·麦克拉克伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuprotect Pty Ltd
Original Assignee
Neuprotect Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904444A external-priority patent/AU2012904444A0/en
Application filed by Neuprotect Pty Ltd filed Critical Neuprotect Pty Ltd
Priority to CN201711032323.9A priority Critical patent/CN107759553A/zh
Publication of CN104955831A publication Critical patent/CN104955831A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
CN201380058798.9A 2012-10-11 2013-10-11 新型类黄酮化合物及其用途 Pending CN104955831A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711032323.9A CN107759553A (zh) 2012-10-11 2013-10-11 新型类黄酮化合物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904444A AU2012904444A0 (en) 2012-10-11 Novel Flavonoid compounds and uses thereof
AU2012904444 2012-10-11
PCT/AU2013/001175 WO2014056038A1 (en) 2012-10-11 2013-10-11 Novel flavonoid compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711032323.9A Division CN107759553A (zh) 2012-10-11 2013-10-11 新型类黄酮化合物及其用途

Publications (1)

Publication Number Publication Date
CN104955831A true CN104955831A (zh) 2015-09-30

Family

ID=50476785

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380058798.9A Pending CN104955831A (zh) 2012-10-11 2013-10-11 新型类黄酮化合物及其用途
CN201711032323.9A Pending CN107759553A (zh) 2012-10-11 2013-10-11 新型类黄酮化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711032323.9A Pending CN107759553A (zh) 2012-10-11 2013-10-11 新型类黄酮化合物及其用途

Country Status (17)

Country Link
US (1) US10316053B2 (https=)
EP (1) EP2906578B8 (https=)
JP (2) JP6567419B2 (https=)
KR (1) KR102169002B1 (https=)
CN (2) CN104955831A (https=)
AU (1) AU2013330222B2 (https=)
BR (1) BR112015008156A2 (https=)
CA (1) CA2887488C (https=)
DK (1) DK2906578T3 (https=)
ES (1) ES2730926T3 (https=)
MX (1) MX368855B (https=)
NZ (1) NZ707087A (https=)
RU (1) RU2647842C2 (https=)
SG (1) SG11201502758SA (https=)
TR (1) TR201908822T4 (https=)
WO (1) WO2014056038A1 (https=)
ZA (1) ZA201502703B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115504970A (zh) * 2022-10-18 2022-12-23 黑龙江中医药大学 一种用于治疗心肌缺血的黄酮类衍生物及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111233806A (zh) * 2020-03-20 2020-06-05 武汉轻工大学 一种3,5,4＇-三乙酰氧基-7-羟基黄酮的制备方法
CN112168976B (zh) * 2020-10-15 2022-11-04 天津科技大学 一种黄酮衍生物前药及合成和作为抗肿瘤药物的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147353A1 (en) * 1999-09-23 2002-10-10 Vereniging Christelijk Wetenschappelijk Anderwijs Novel flavonoids
CN101137639A (zh) * 2005-03-11 2008-03-05 霍华德弗洛里生理医学实验研究所 类黄酮化合物及其用途
CN102617672A (zh) * 2012-02-24 2012-08-01 大连大学 一种金花茶黄酮苷及其制备方法和用途
CN102631362A (zh) * 2012-01-19 2012-08-15 中国人民解放军第二军医大学 射干异黄酮类化合物在制备预防和治疗紫外线致皮肤损伤药物中的应用
CN102697768A (zh) * 2012-06-07 2012-10-03 中国人民解放军第二军医大学 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06161129A (ja) * 1992-11-25 1994-06-07 Mita Ind Co Ltd 電子写真感光体
US6555523B1 (en) * 1999-07-08 2003-04-29 Patrick T. Prendergast Use of cirsiliol and derivatives to treat infections
JP2003019867A (ja) 2001-04-19 2003-01-21 Mitsubishi Chemicals Corp 光記録媒体
GB0125532D0 (en) * 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators
WO2006030322A2 (en) 2004-09-17 2006-03-23 University Of Manitoba Use of fla vone/fla vanone derivatives fn the treatment or prevention of respiratory conditions
US20060084615A1 (en) * 2004-10-20 2006-04-20 Chan Albert S Puerarin derivatives and their medical uses
JP2007230145A (ja) 2006-03-02 2007-09-13 Mitsubishi Chemicals Corp 光学記録媒体の記録層形成用色素、及びそれを用いた光学記録媒体、その光学記録媒体の記録方法
WO2008011538A2 (en) 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
US7863323B1 (en) * 2006-10-27 2011-01-04 The University Of Melbourne Flavonols
DE102008012909A1 (de) 2008-03-06 2009-09-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen
CN101244057B (zh) 2008-03-11 2010-06-02 中国人民解放军第二军医大学 具有降血脂作用的3-取代氧基-3',4'-二甲氧基黄酮类化合物
JP5424296B2 (ja) 2008-08-28 2014-02-26 静岡県公立大学法人 フラボン誘導体の製造方法およびシアル酸転移酵素阻害剤
EP2424541A2 (en) 2009-04-27 2012-03-07 Limerick BioPharma, Inc. Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
JP2012044944A (ja) 2010-08-27 2012-03-08 Railway Technical Research Institute トルエン検出方法
DE102011104441A1 (de) * 2011-06-16 2012-12-20 Fujitsu Technology Solutions Intellectual Property Gmbh Schaltnetzteil, Betriebsverfahren und Verwendung eines Schaltnetzteils in einem Computer
WO2013020184A1 (en) 2011-08-11 2013-02-14 Neuprotect Pty Ltd Flavonoid compounds, and methods of use thereof
US9664695B2 (en) * 2012-10-02 2017-05-30 Sphingotec Gmbh Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147353A1 (en) * 1999-09-23 2002-10-10 Vereniging Christelijk Wetenschappelijk Anderwijs Novel flavonoids
CN101137639A (zh) * 2005-03-11 2008-03-05 霍华德弗洛里生理医学实验研究所 类黄酮化合物及其用途
CN102631362A (zh) * 2012-01-19 2012-08-15 中国人民解放军第二军医大学 射干异黄酮类化合物在制备预防和治疗紫外线致皮肤损伤药物中的应用
CN102617672A (zh) * 2012-02-24 2012-08-01 大连大学 一种金花茶黄酮苷及其制备方法和用途
CN102697768A (zh) * 2012-06-07 2012-10-03 中国人民解放军第二军医大学 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAOJIAN WU, ET AL.,: "Evaluation of 3,3′,4′-Trihydroxyflavone and 3,6,4′-Trihydroxyflavone (4′-O-Glucuronidation) as the in Vitro Functional Markers for Hepatic UGT1A1.", 《MOL. PHARMACEUTICS》 *
吴慧.: "201380058798.9", 《STN检索报告》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115504970A (zh) * 2022-10-18 2022-12-23 黑龙江中医药大学 一种用于治疗心肌缺血的黄酮类衍生物及其制备方法

Also Published As

Publication number Publication date
EP2906578B1 (en) 2019-05-08
RU2015117641A (ru) 2016-11-27
WO2014056038A1 (en) 2014-04-17
EP2906578A4 (en) 2016-03-23
JP2018184414A (ja) 2018-11-22
EP2906578A1 (en) 2015-08-19
NZ707087A (en) 2016-04-29
MX368855B (es) 2019-10-18
ZA201502703B (en) 2016-11-30
SG11201502758SA (en) 2015-05-28
RU2647842C2 (ru) 2018-03-21
KR20150096376A (ko) 2015-08-24
TR201908822T4 (tr) 2019-07-22
EP2906578B8 (en) 2019-06-26
US10316053B2 (en) 2019-06-11
ES2730926T3 (es) 2019-11-13
DK2906578T3 (da) 2019-07-15
JP6567419B2 (ja) 2019-08-28
AU2013330222A1 (en) 2015-05-21
US20150259373A1 (en) 2015-09-17
CN107759553A (zh) 2018-03-06
AU2013330222B2 (en) 2016-05-12
KR102169002B1 (ko) 2020-10-23
CA2887488A1 (en) 2014-04-17
CA2887488C (en) 2020-07-14
JP2015533128A (ja) 2015-11-19
MX2015004578A (es) 2016-03-04
BR112015008156A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
EP1856085B1 (en) Flavonoid compounds and uses thereof
WO2009064485A1 (en) Antioxidant flavonoid derivatives
EP4196127B1 (en) Nicotinamide mononucleotide derivatives in the treatment and prevention of sickle cell disease
CN103781472A (zh) 丙泊酚苷衍生物的合成和使用
JP2018184414A (ja) 新規フラボノイド化合物およびその使用
EA014909B1 (ru) Кристаллические формы пролекарства на основе амида гемцитабина, композиции на их основе и их применение
CN113214097B (zh) 治疗阿尔茨海默病的化合物
JP7003057B2 (ja) グリコシル化クロリンｅ６誘導体、または、その薬学的に許容される塩、医薬組成物、標的を破壊する方法、および、グリコシル化クロリンｅ６誘導体、またはその薬学的に許容される塩の製造方法
WO2020019994A1 (zh) 一类具有神经保护作用的化合物及其制备方法和用途
JPWO2002020536A1 (ja) テトラフェニルバクテリオクロリン誘導体およびそれを含む組成物
MC898A1 (fr) Composés organiques
CN108904481A (zh) 邻羟基查尔酮类似物在制备抗氧化药物中的应用
JP3831953B2 (ja) ７−グリコシロキシベンゾピラン誘導体及びそれを有効成分とする抗アレルギー剤
JPH06503804A (ja) アニオン性フラノース誘導体、その製造法および使用法
JP7634114B2 (ja) ヒアルロナンコンジュゲートの使用
WO1995023796A1 (en) Guanylhydrazone derivative
WO2002096921A1 (fr) Nouveau derive glucose induisant l'apoptose, procede de production et utilisation comme medicament
KR20240040049A (ko) 신규 화합물 및 이를 포함하는 염증성 질환과 암에 대한 진단 및 치료에 사용되는 mri 조영제
JP2025531133A (ja) ユビキチン特異的プロテアーゼ阻害剤としてのカルボニル縮合複素環誘導体
WO2024122113A1 (ja) 化合物、ナノ粒子、医薬、及びナノ粒子の製造方法
CN119698417A (zh) 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物
ES2202212T3 (es) Benzofenona-a-d.glicopiranosidos, preparacion y uso terapeutico.
JP2023542455A (ja) ３－デオキシ－２－ケトアルドン酸窒素含有誘導体、その製造方法及びその使用
WO2010090234A1 (ja) 12-デオキシフシコクシン糖鎖改変誘導体およびその用途
JPH07316179A (ja) リボース誘導体および放射線障害防護剤

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150930

RJ01 Rejection of invention patent application after publication